Samyang Holdings Lifting Team 'Croquis' Holds Symposium at International Aesthetic Plastic Surgery Conference

Samyang Holdings BioPharm Group announced on the 5th that it held a symposium on the features and procedures of the lifting thread "Croquis" at the "International Master Course on Aging Science (IMCAS) 2024," the world's largest international aesthetic surgery conference held in Paris, France.

On the 3rd (local time) at the 'IMCAS 2024' during the 'Croquis' symposium, Dr. Clara Santos, a dermatologist from Brazil, introduced the product's features and advantages.
[Photo by Samyang Holdings]

At this symposium, Dr. Lee Won, president of the Minimally Invasive Plastic Surgery Society (MIPS) of the Korean Society of Plastic and Reconstructive Surgeons, and Dr. Clara Santos, a dermatologist from Brazil, presented a procedure using Croquis under the theme "Croquis Master Class: Fat Repositioning Procedure Using Double Lifting" and shared clinical cases.

In the presentation, they introduced results showing that when performing double lifting (a lifting technique using two types of threads) with four types of Croquis, the fat repositioning effect varied depending on the type and combination of threads and the patient's skin condition. The presenters shared various clinical cases, recommending the optimal Croquis combinations suitable for treatment areas and patient conditions, and confirmed the safety of Croquis through patient outcomes.

Croquis is a biodegradable lifting thread that naturally decomposes in the human body after a certain period. Its main component is polydioxanone (PDO), a biocompatible polymer. It received the European medical device directive "CE MDD" certification in 2019. Currently, it is exported to 29 countries worldwide, including Europe, Japan, and Latin America, and is undergoing approval procedures for marketing in the United States.

Dr. Lee Won, president of the society, said, "Croquis is a product with excellent procedural effects and safety, resulting in high satisfaction among both medical professionals and patients," adding, "I am honored to share the experience and know-how accumulated through direct procedures in the field with aesthetic medical professionals worldwide through this symposium."

Samyang Holdings also opened a promotional booth at the conference to showcase its self-developed polymer filler "Rapullen." Rapullen's main component is polycaprolactone (PCL), a medical biodegradable polymer. It features effects that last over two years, with Samyang Holdings' patented technology minimizing foreign body sensation and providing natural volume. It received approval from the Korean Ministry of Food and Drug Safety in 2021. Starting with its launch in Indonesia, the company is accelerating its overseas expansion, having signed export partnership agreements last year with Chinese medical device and aesthetic specialty companies.

Lee Young-jun, CEO of Samyang Holdings BioPharm Group, stated, "Croquis and Rapullen are aesthetic products developed by consolidating Samyang Group's long-accumulated polymer material research and development capabilities," adding, "We will accelerate the expansion of the rapidly growing global aesthetic market based on excellent efficacy and safety."